Actively Recruiting
Characterizing Proximal Risk for Depressive Symptoms and Suicidal Ideation With Acute Cannabis Use and Withdrawal Among Adolescents Using Ecological Momentary Assessment
Led by Massachusetts General Hospital · Updated on 2026-03-03
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying adolescents aged 12 to 18 who use cannabis daily or nearly daily and have current depression symptoms. The study aims to understand how acute cannabis use and withdrawal affect depression and suicidal thoughts, focusing on mood, substance use patterns, and suicidal ideation. The goal is to develop accessible and personalized interventions to reduce depression and suicide risk in this population. The study involves 200 participants who will take part in a 10-week program divided into three phases. The first phase is a 2-week baseline period where participants use cannabis as usual while reporting mood and use patterns through smartphone monitoring. After this, participants are randomly assigned to one of two groups for eight weeks one group will abstain from cannabis with incentives for staying abstinent, and the other will continue their usual cannabis use without restrictions. Both groups complete smartphone assessments during weeks 1 and 8 of this phase. Participants will attend 12 visits over approximately 10 weeks for urine tests to verify cannabis use or abstinence, and complete questionnaires and interviews about substance use, cravings, withdrawal symptoms, mood, and suicidal thoughts. The study measures cannabis use, motivation to use cannabis for mood improvement, mood depletion, cognitive effects, activation levels, passive suicidal thoughts, suicidal urges, and urges for self-injury at various time points to monitor changes throughout the study.
CONDITIONS
Brief Title
Cannabis, Linked Emotions, and Adolescent Risk Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 12 to 18 years
- Current daily or near daily cannabis use (at least 4 days per week on average)
- Score of 5 or higher on the PHQ-9 depression questionnaire
- Access to an internet-capable smartphone (iOS or Android)
- Provide at least one collateral contact for risk monitoring
- Provide informed assent if under 18, or consent if 18 years old
- Respond to at least 50% of ecological momentary assessment prompts during the first phase
- No immediate plan to stop cannabis use in the next 3 months
- Positive urine test for cannabis at baseline
You will not qualify if you...
- Any factor impairing ability to understand or participate, including intoxication at consent
- Using cannabis more than 4 times per day on average
- Inability to speak or write English fluently
- Significant cognitive impairment such as psychosis, intellectual disability, developmental delay, or neurodegenerative disease
- Current diagnosis of epilepsy
- Under legal protection of the state (wards of the state)
- Incorrect knowledge about responding to suicidality prompts
- Unable or unwilling to wear a Fitbit device
Research Team
R
Randi M Schuster, PhD
J
Julia Jashinski, MSW
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here